AbbVie ABBV has successfully navigated the loss of exclusivity (LOE) for its flagship drug, Humira, by launching two newer ...

AbbVie edges ahead of Bristol Myers with strong Skyrizi and Rinvoq growth, offsetting Humira declines and portfolio headwinds.

There’s really no such thing as a “no brainer” stock pick. I’d say that some opportunities are more compelling than others.

The author includes U.S. and Canadian names, organized by country. Each company comes with a business summary, plus a bull ...

The global Botulinum Toxins Market, valued at US$8.1 billion in 2024 stood at US$8.9 billion in 2025 and is projected to advance at a ...

The pharma began its outreach to the HS community well before securing Bimzelx’s approval in the indication. In the spring of ...

AbbVie has broken ground on a new $223 million expansion of its biologics manufacturing facility in Singapore, creating around 100 new jobs.